葡萄糖类-1受体激活剂对糖尿病外围神经病变中的轴突功能的影响
Roshan Dhanapalaratnam1,2, Tushar Issar1, Ann M Poynten3
1School of Clinical Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
Journal of neurophysiology
|November 25, 2024
概括
类似葡萄糖-1受体激活剂 (GLP-1RA) 疗法在治疗糖尿病外围神经病变 (DPN) 中表现有前途. 这种治疗改善了临床分数和神经功能,通过增强-活动来潜在地逆转神经损伤.
科学领域:
- 神经学 神经学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病外围神经病变 (DPN) 影响了2型糖尿病患者的一半.
- 周围神经系统GLP-1受体是DPN的潜在治疗点.
研究的目的:
- 调查GLP-1受体激动剂 (GLP-1RA) 疗法在改善DPN的临床和神经生理结果方面的疗效.
- 探索GLP-1RA疗法可以逆转轴突功能障碍的机制.
主要方法:
- 对14名患有DPN的参与者进行了前性研究,他们接受了semaglutide或dulaglutide治疗.
- 临床评估,神经导电研究和轴突刺激能力评估在基线和3个月.
- 结合了10名先前接受过exenatide治疗的参与者的数据;对兴奋度数据的数学建模.
主要成果:
- 在GLP-1RA治疗3个月后,临床神经病症评分 (TNS) 显著改善 (P=0.005).
- 在神经传导研究中增强了外围神经振幅 (P=0.013).
- 轴突刺激性变化表明改善了Na+/K+-ATPase功能和Na+透性.
结论:
- GLP-1RA疗法有效地改善了DPN患者的临床和神经生理结果.
- 该机制涉及通过增强的Na+/K+-ATPase功能来逆转轴突功能障碍.
- GLP-1RA治疗提供了一种潜在的策略来抵消DPN的渐进性质.
相关概念视频
Glucagon-like Receptor Agonists
298
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
298
Dipeptidyl Peptidase 4 Inhibitors
171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
159
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
159
Oral Hypoglycemic Agents: Biguanides and Glitazones
174
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
174
Oral Hypoglycemic Agents: Glinides
141
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
141
Hormones Regulating Blood Glucose
3.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.1K


